Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Ofgem confirms 2pc energy price cap rise from October

(Sharecast News) - Millions of Britons will face higher energy bills this autumn after Ofgem confirmed a 2% increase in its quarterly price cap, slightly above market expectations.

From 1 October, the annual cost for a typical dual-fuel household will rise to £1,755, up £35 from the current level. The increase applies across England, Scotland and Wales, and will remain in place for three months, when Ofgem will adjust the cap again, primarily in response to wholesale market movements.

Households on means-tested benefits will automatically receive the £150 Warm Home Discount this winter, with eligibility widened to remove previous restrictions linked to property size.

Standing charges will rise by 4% for electricity and 14% for gas, adding further pressure to budgets already stretched by elevated energy costs, with campaigners already warning that price cap adjustment could lead to another winter of financial strain for vulnerable households.

Ofgem said the changes were necessary to balance affordability with supplier sustainability, and urged consumers to check for cheaper fixed-rate deals where available. The regulator also reminded consumers that the cap was not a limit on total spend, noting that for every £100 currently spent on energy each year, households can now expect to pay roughly £2 more under the new rates.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.